Opposingly, activin treatment reduced the tumor burden, increased the survival time, and increased the pro-inflammatory profile of isolated CD4+ T-cells in a Lewis lung carcinoma (LLC) mouse model of lung cancer [15]. This evidence concerns the gene INHBE and lung carcinoma.